



Iowa Department of Human Services

Terry E. Branstad
Governor

Kim Reynolds
Lt. Governor

Charles M. Palmer
Director

Iowa Medicaid Pharmaceutical and Therapeutics (P & T) Committee Meeting April 17, 2014

Location: Learning Resource Center
Community Room
3550 Mills Civic Parkway
West Des Moines, IA 50265

Time: 9:30 a.m. – 4:30 p.m.

Tentative Agenda

1. Welcome & Introductions
 - a) Committee Members and Staff
 - b) Approval of the minutes
2. Update
 - a) Preferred Drug List (PDL)
 - b) Medicaid Drug Rebate Issues
 - c) Prior Authorization Criteria/Pro-DUR edits
 - d) Legislation
 - e) IME Updates
3. Public Comment (**See attachment 1 for Conflict of Interest Disclosure**)
4. Closed Executive Session
 - a) Approval of the minutes
 - b) Economic Review of the Iowa Medicaid Preferred Drug List, Newly Released Drugs, Newly Released Generic Drugs, New Dosage Forms, and Contracts
 - c) Review and discussion of the Confidential Public Comments
5. Preferred Drug List (PDL) discussion and deliberation
(**See attachment 2 for order of discussion**)
6. Final Recommendations by the P & T Committee on the Iowa Medicaid Preferred Drug List
7. Review of Newly Released Drugs
(**See attachment 3 for order of discussion**)
8. Final Recommendations by the P & T Committee on Newly Released Drugs (Open Session)
9. Review of Newly Released Generic Drugs, Dosage Forms or Strengths
(**See attachment 4 for order of discussion**)
10. Final Recommendations by the P & T Committee on Newly Released Generic Drugs, Dosage Forms or Strengths
11. Preview of next meeting

****Disclaimer:** Executive Sessions may be necessary during the deliberation process**

www.iowaMedicaidPDL.com

Next scheduled meeting: August 21, 2014 9:30am - 4:30pm

For more information contact Erin Halverson at ehalver@dhs.state.ia.us or (515) 974-3126

Attachment 1

**Iowa Medicaid Pharmaceutical and Therapeutics (P&T) Committee
Speaker Conflict of Interest Disclosure**

The Iowa Medicaid Pharmaceutical and Therapeutics (P&T) Committee and persons speaking or presenting to the Iowa Medicaid P&T Committee are asked to disclose any financial or other affiliation with organizations that may have a direct or indirect interest in the business in front of the Committee. Those persons speaking or presenting at the P&T Committee meetings are asked to disclose potential conflicts on this form. P&T Committee members disclose potential conflicts each year on a separate form.

A financial interest may include, but is not limited to, being a shareholder in the organization, being on retainer with the organization, having research or honoraria paid by the organization, or receiving other forms of remuneration from an organization. An affiliation may include holding a position on an advisory committee or some other role or benefit to a supporting organization.

The existence of such a financial relationships or affiliation does not necessarily constitute a conflict of interest and will not preclude an individual from participating or addressing the P&T Committee. This policy is intended to openly identify any potential conflicts so that the P&T Committee members and the public are able to form their own judgments.

Your responses below will be read out loud before your presentation to the P&T Committee.

Please check the box of the statement that best applies.

Statement of No Conflicts

I do not have a current or recent (within the last 12 months) financial arrangement or affiliation with any organization that may have a direct interest in the business before the Iowa Medicaid P&T Committee.

Disclosures

I have a financial interest, affiliation or am employed by an organization that may have a direct interest in the business before the Iowa Medicaid P&T Committee

I refuse to state my affiliations

Organization (List additional on the back of the form.)	Role/Relationship (List additional on the back of the form.)

(print name)

(signature)

(date)

Attachment 2

Iowa Medicaid Preferred Drug List

Disclaimer: The Iowa P&T Committee reserves the right to re-evaluate all medications within the same therapeutic category as those on the agenda scheduled to be discussed for the PDL Review, New Drug Review, New Generic Drug Review, and New Dosage Forms Review and vote to change the PDL status of other medications currently on the PDL. It is the responsibility of the drug manufacturer to provide representation, if necessary, at the P&T Committee Meeting when a competitor's product is on the agenda for discussion.

1. Recommend to change cyproheptadine to Non-Preferred to maximize cost savings to the program.
2. Recommend to change Ritalin to Non-Preferred with Conditions to maximize cost savings to the program (methylphenidate tablets will remain preferred with conditions).
3. Recommend to change Syprine to Non-Preferred to maximize cost savings to the program.

Attachment 3
Newly Released Drugs

Disclaimer: The Iowa P&T Committee reserves the right to re-evaluate all medications within the same therapeutic category as those on the agenda scheduled to be discussed for the PDL Review, New Drug Review, New Generic Drug Review, and New Dosage Forms Review and vote to change the PDL status of other medications currently on the PDL. It is the responsibility of the drug manufacturer to provide representation, if necessary, at the P & T Committee Meeting when a competitor's product is on the agenda for discussion.

1. Adempas- Recommend status on the PDL as Non-Preferred with Conditions
2. Brintellix- Recommend status on the PDL as Non-Preferred
3. Fetzima- Recommend status on the PDL as Non-Preferred
4. Fycompa- Recommend status on the PDL as Non-Preferred
5. Gilotrif- Recommend status on the PDL as Non-Recommended
6. Olysio- Recommend status on the PDL as Non-Preferred with Conditions
7. Opsumit- Recommend status on the PDL as Non-Preferred with Conditions
8. Sovaldi- Recommend status on the PDL as Preferred with Conditions

Attachment 4

Newly Released Generic Drugs, New Dosage Forms, New Drug Names, and New drug Strengths

Disclaimer: The Iowa P&T Committee reserves the right to re-evaluate all medications within the same therapeutic category as those on the agenda scheduled to be discussed for the PDL Review, New Drug Review, New Generic Drug Review, and New Dosage Forms Review and vote to change the PDL status of other medications currently on the PDL. It is the responsibility of the drug manufacturer to provide representation, if necessary, at the P&T Committee Meeting when a competitor's product is on the agenda for discussion.

NEWLY RELEASED GENERIC DRUGS		
Drug Name	Brand Name/Status on PDL/RDL	PDL/RDL Recommendation
Abacavir/ Lamivudine/ Zidovudine	Trizivir / Recommended	Non-Recommended
Ceftibuten	Cedax / Non-Preferred	Non-Preferred
Clonidine ER	Kapvay/ Non-Preferred with Conditions	Non-Preferred with Conditions
Dexmethylphenidate ER	Focalin XR / Preferred with Conditions	Non-Preferred with Conditions
Diclofenac Gel 3%	Solaraze / Non-Preferred	Non-Preferred
Duloxetine	Cymbalta / Preferred with Conditions	Non-Preferred with Conditions
Fluocinonide Cream 0.1%	Vanos / Non-Preferred	Non-Preferred
Gatifloxacin	Zymaxid / Non-Preferred	Non-Preferred
Lidocaine Patch	Lidoderm / Non-Preferred with Conditions	Non-Preferred with Conditions
Mycophenolic acid	Myfortic / Recommended	Non-Recommended
Niacin ER	Niaspan / Preferred	Non-Preferred
Paricalcitol	Zemplar / Non-Preferred	Non-Preferred
Rabeprazole	Aciphex / Non-Preferred with Conditions	Non-Preferred with Conditions
Sirolimus	Rapamune / Recommended	Non-Recommended
Telmisartan	Micardis / Preferred with Conditions	Non-Preferred with Conditions
Telmisartan / Amlodipine	Twynsta / Non-Preferred with Conditions	Non-Preferred with Conditions
Tobramycin Nebulization Solution	Tobi / Preferred	Non-Preferred
Tolterodine ER	Detrol LA / Non-Preferred	Non-Preferred

NEW DRUG DOSAGE FORMS/STRENGTHS/COMBINATIONS

Bethkis	Tobi / Preferred	Preferred
Epaned	Enalapril Tablets / Preferred	Non-Preferred
Khedezla ER	Pristiq / Non-Preferred with Conditions	Non-Preferred with Conditions
Procysbi	Cystagon / Non-Preferred	Non-Preferred
Rixubis	Benefix / Recommended	Non-Recommended
Trokendi XR	Topiramate Tablets / Preferred	Non-Preferred with Conditions
Versacloz	Clozapine Tablets / Preferred	Non-Preferred
Zorvolex	Diclofenac Tablets / Preferred	Non-Preferred with Conditions